Centene (CNC) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Natera (NTRA) has outperformed Centene (CNC) over the past year, gaining 134.7% versus a gain of 69.2%. Over five years, NTRA leads with a +257.1% price change compared with -0.5% for CNC. Natera is the larger company by market cap ($55.93 billion vs $31.97 billion), about 1.7 times the size.
Centene converts more of its revenue into profit, with a net margin of -3.4% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNC | NTRA |
|---|---|---|
| Share price | $64.73 | $388.02 |
| Market cap | $31.97B | $55.93B |
| 1-day change | -0.41% | -1.91% |
| YTD return | +57.93% | +72.67% |
| 1-year return | +69.16% | +134.71% |
| 5-year return | -0.51% | +257.10% |
| Forward P/E | 12.10 | — |
| EPS (TTM) | $-10.44 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $194.78B | $2.31B |
| Revenue growth (YoY) | +19.44% | +35.90% |
| Net income (latest FY) | $-6.67B | $-208.16M |
| Gross margin | 7.30% | — |
| Operating margin | -3.91% | -13.44% |
| Net margin | -3.43% | -9.03% |
| 52-week high | $69.63 | $437.41 |
| 52-week low | $31.63 | $167.99 |
| Distance from 52-week high | -7.04% | -11.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +10.90% | -2.73% |
| Average volume | 4.57M | 1.44M |
| Shares outstanding | 494.00M | 144.14M |
| Employees | 61,100 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTRA has outperformed CNC by 65.6 percentage points over the past year.
- Centene is more profitable, keeping -3.4 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs +19.44%).
About Centene
CNC stock →Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other.
Health Care · Medical Specialities · 61,100 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
CNC vs NTRA FAQ
Which is bigger, Centene or Natera?
Natera (NTRA) is larger, with a market capitalization of $55.93B compared with $31.97B for Centene (CNC).
Which stock has performed better over the past year, CNC or NTRA?
NTRA returned +134.71% over the past 12 months, compared with +69.16% for CNC (price return, excluding dividends). Past performance does not predict future results.
Are Centene and Natera in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.